Polaris Group (TPE:6550) ROCE % : -40.69% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Polaris Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Polaris Group's annualized ROCE % for the quarter that ended in Dec. 2024 was -40.69%.

Polaris Group ROCE % Historical Data

The historical data trend for Polaris Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polaris Group ROCE % Chart

Polaris Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-18.84

-13.85

-13.87

-17.02

-29.63

Polaris Group Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-23.43	-18.69	-25.26	-34.58	-40.69

Polaris Group ROCE % Calculation

Polaris Group's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-2488.481	/	( ( (9137.121 - 959.373)	+	(9090.44 - 468.894) )	/ 2 )
	=	-2488.481	/	( (8177.748	+	8621.546)	/ 2 )
	=	-2488.481	/	8399.647
	=	-29.63 %

Polaris Group's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-3356.432	/	( ( (8296.88 - 422.858)	+	(9090.44 - 468.894) )	/ 2 )
	=	-3356.432	/	( ( 7874.022	+	8621.546 )	/ 2 )
	=	-3356.432	/	8247.784
	=	-40.69 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Polaris Group (TPE:6550) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Polaris Group ROCE % Related Terms

Thank you for viewing the detailed overview of Polaris Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Polaris Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Polaris Group (TPE:6550) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

NO.298, Ruiguang Road, 7th floor, Neihu District, Taipei, TWN

Website

https://www.polarispharma.com

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.

Polaris Group Headlines

No Headlines